Critical Assessment of the Status of Biomarkers for Alzheimer’s disease
Journal: Journal of Parkinson’s disease and Alzheimer's disease (Vol.1, No. 1)Publication Date: 2014-12-30
Authors : Paul L. Wood; Julie A. Wood;
Page : 1-4
Keywords : Biomarkers; Alzheimer’s disease; pathology;
Abstract
Objective: We undertook a critical analysis of the status of the progress in the development of biomarkers for the detection of Alzheimer’s disease (AD). Methods: Biomarker studies involving imaging, metabolomics, lipidomics, proteomics, transcriptomics and microRNAs were assessed from publications between 2004 and 2014. Results: Extensive efforts have been applied to the development of minimally invasive and inexpensive assays for the early detection of AD. However, the failure to replicate findings between laboratories has presented a significant challenge in validating assays for clinical use. Larger scale studies and collaborations are required to standardize sample collection and storage, analytical methodology, and to control for heterogeneity in the AD patient population. Conclusions: Since cognitive testing cannot detect the presymptomatic stages of AD, validated biomarkers are essential for advancing both AD research and clinical practice. Despite intensive research over the last 10 years, there currently are no validated biomarkers for the early detection of AD.
Other Latest Articles
- Alcohol Treatment of Oral Streptococcus Spp. Increased the Entry of Human Papillomavirus Type 16 into Non-Malignant and Oral Squamous Cell Carcinoma Cells
- Oral Health: A Window into General Health
- Pediatric Bitewing Exposure to Organs of the Head and Neck Through the Use of Juvenile Anthropomorphic Phantoms
- Food Circles: Envisioning How Eating a Variety of Foods Over Time will Benefit Health
- Multiple Sclerosis: A Family Practice Perspective
Last modified: 2015-06-23 20:10:11